丽珠集团：P-CAB产品片剂已报产，注射剂进入II期临床

Core Viewpoint - Lijun Group's P-CAB product JP-1366 has been submitted for market approval for tablet form in July 2024, and the injection form has entered Phase II clinical trials in October, marking it as the first P-CAB drug in China to conduct research on injection form [1] Group 1: Product Development - The company is leveraging its established product portfolio and sales channels in the gastrointestinal field to accelerate market penetration of JP-1366 [1] - JP-1366 is expected to create a synergistic effect with existing PPI products [1] Group 2: Market Potential - The P-CAB market is experiencing rapid growth, with projected domestic sales reaching approximately 1.25 billion in 2024, representing an 81% year-on-year increase [1]